

## International Journal of Advanced Biochemistry Research



ISSN Print: 2617-4693  
ISSN Online: 2617-4707  
IJABR 2025; 9(1): 941-943  
[www.biochemjournal.com](http://www.biochemjournal.com)  
Received: 02-11-2024  
Accepted: 06-12-2024

**Hind F Jawad**  
Department of Clinical  
Laboratory Science, College of  
Pharmacy, University of  
Baghdad, Baghdad, Iraq

**Shatha H Ali**  
Department of Clinical  
Laboratory Science, College of  
Pharmacy, University of  
Baghdad, Baghdad, Iraq

**Tawfeeq FR Al-Auqbi**  
The National Center for  
Diabetes Treatment &  
Research, College of Medicine  
Al Mustansiriya University,  
Baghdad, Iraq

## Estimation of serum L-carnitine levels in relation to insulin and hs-CRP in Type2 Iraqi diabetics

Hind F Jawad, Shatha H Ali, Tawfeeq FR Al-Auqbi

DOI: <https://doi.org/10.33545/26174693.2025.v9.i11.3674>

### Abstract

This study aims to focus on serum levels of L-carnitine, insulin, high sensitivity C-reactive protein (hs-CRP), fasting serum glucose FSG, Homeostatic Model Assessment-Insulin Resistance HOMA-IR in type2 Iraqi diabetic patients compared with apparently healthy controls. A case-controlled study included (84) Iraqi subjects were classified into two groups: diabetics (45) and controls(39). L-carnitine and insulin levels were significantly ( $p<0.05$ ) lowered in diabetics as compared to controls, while high sensitivity C-Reactive Protein (hs-CRP), FSG, HOMA-IR were significantly ( $p<0.05$ )elevated in their serums, furthermore, the serum insulin levels have a positive significant correlation with serum L-carnitine levels in both groups, illustrating the influence of L-carnitine in ameliorating diabetes risks by improving glucose level, and ameliorate insulin resistance, beside their anti-inflammatory effect. These findings suggest using of L-carnitine as a therapy in diabetes mellitus and insulin resistance.

**Keywords:** L-carnitine, insulin, hs-CRP, HOMA-IR, T2DM

### Introduction

The prevalence of diabetes in 2021 had been reported to be about 537 million people and is expected to rise to 783 million in 2045 worldwide [1]. A conjugation of demographic and economic changes, with the association of large shifts in physical activity and dietary patterns, properly considered a primary drivers for the rise in diabetes in low- and middle-income countries [2]. Diabetes mellitus (DM) is a chronic disease causing an insulin action resistant that leads to prolonged hyperglycemia besides metabolic disorders of lipids, and protein [3]. Type 2 diabetes (T2DM), the most common type of DM, is characterized by insulin resistance state that leads to a progressive decrease of adequate insulin secretion from  $\beta$ -cells [4]. Many results show the increased levels of Homeostatic Model Assessment-Insulin Resistance HOMA-IR and fasting serum glucose FSG in diabetics when compared to non-diabetics [5]. Although individual susceptibility to T2DM is determined by genetic predisposition, which is related to more than 88 genetic loci involved in susceptibility to T2DM [4], the increase in obesity, a sedentary lifestyle, industrialization and energy-dense diets are responsible for making the T2DM a wide spread state [6]. Carnitine was discovered in 1905 as one of muscle component, while the structure were discovered after about 20 years [7], the synthesis occurs in the liver, kidneys, and brain [8]. The normal level of total carnitine in plasma is 45  $\mu\text{mol/L}$  to 91  $\mu\text{mol/L}$ , free carnitine is 36  $\mu\text{mol/L}$  to 74  $\mu\text{mol/L}$ , and acyl carnitine is 6  $\mu\text{mol/L}$  to 23  $\mu\text{mol/L}$  [9]. L-Carnitine decrease fasting glucose serum level [10]. CRP is a 206-amino acid [11]. C-reactive protein (CRP) estimation is considered as a marker for systemic inflammation [12]. This study is aimed to estimate the serum levels of L-carnitine, in relation to insulin, high sensitivity C-Reactive Protein (hs-CRP), fasting serum glucose, HOMA-IR and their correlations with each others in diabetic patients compared with apparently healthy controls.

### Materials and Methods

#### Design of the study

A case-controlled study was conducted at The National Center for Diabetes/College of Medicine Al- Mustansiriya University. The study was approved by and obtained the Ethical approval of The Committee of The Post Graduate Studies/The College of Pharmacy. The diabetic patients were selected from the out-patient clinic under the supervision of an

**Corresponding Author:**  
**Hind F Jawad**  
Department of Clinical  
Laboratory Science, College of  
Pharmacy, University of  
Baghdad, Baghdad, Iraq

endocrinologist from patients attending The National Center for Diabetes/Medicine College Al Mutansryia University. The selection criteria of patients was listed in a questionnaire included having type 2 DM for at least 1 year, aged 18 years or older, fasting over last night, while the exclusion criteria were malignant, endocrinopathy, renal, chronic liver diseases. Eighty- four subjects included in the present study, were categorized into two groups:

**Group-1 diabetic patients:** include forty five diabetic patients (17 males & 28 females) aged between (25-44) years, Group -2 control subjects: include thirty nine subjects (19 males & 20 females) aged between (30-65) years were chosen from general population to be apparently healthy. Venous blood specimen (7 ml) was withdrawn from each subject after an overnight fasting. The samples of blood were placed into a gel tube (no anticoagulant) to permit clotting before centrifugation for 10 minutes. The obtained serum was stored as aliquots and were kept frozen (-20 °C) until their assay for insulin, hs- CRP, L-Carnitin, by specific ELISA kits, besides measuring fasting serum glucose (FSG) in automated Kenza 240 TX Biochemical autoanalyzer device. The results were expressed as (mean  $\pm$  standard deviation (SD) of mean). To explore the normality of the data the Shapiro-Wilk test was conducted to all parameters.

The normally distributed variables were managed by t test to compare the two studied groups. Pearson's correlation coefficient (r) was run to find out the statistical significant correlations between measured parameters. P value less than 0.05 was accepted as a significance difference. The analyses were conducted using the Statistical Package for the Social Science (SPSS), version 25.

**Table 1:** Analytical kits

| Analyte               | Suppliers                                           |
|-----------------------|-----------------------------------------------------|
| Glucose               | BIOLABO Diagnostic/France                           |
| hs C-Reactive Protein | Demeditec Diagnostics/Germany                       |
| Insulin               | Demeditec Diagnostics/Germany                       |
| L- Carnitine          | Shanghai Yehua Biological Technology Co., Ltd/China |

## Results

FSG, HOMA-IR, hs-CRP were significantly higher in diabetics, while fasting insulin, L-carnitine shows significantly lowered levels in diabetics as compared to controls. The diabetics is older ( $52.111 \pm 10.375$ ) than controls ( $33.333 \pm 5.488$ ), the duration of disease in diabetics is ( $6.42 \pm 4.801$ ), Table 2.

**Table 2:** Descriptive Data of Control & Diabetic Patients

|                                                               | Control (n=39)        | DM (n=45)               | P –value      |
|---------------------------------------------------------------|-----------------------|-------------------------|---------------|
| Age (year)                                                    | $33.333 \pm 5.488$    | $52.111 \pm 10.375$     | $< 0.0001^*$  |
| Gender (M/F)                                                  | 19/20                 | 17/28                   | -----         |
| Disease duration (year)                                       | -----                 | $6.42 \pm 4.801$        | -----         |
| L-carnitin                                                    | $31.925 \pm 7.969209$ | $21.13333 \pm 2.608128$ | $< 0.0001^*$  |
| hs-CRP ( $\mu\text{g/ml}$ )                                   | $5.492 \pm 2.905$     | $17.937 \pm 5.979$      | $< 0.0001^*$  |
| Insulin ( $\mu\text{IU/ml}$ )                                 | $13.502 \pm 6.165$    | $8.411 \pm 1.161$       | $< 0.0001^*$  |
| FSG ( mg/ml)                                                  | $90.0 \pm 19.351$     | $176.555 \pm 38.927$    | $< 0.0001^*$  |
| HOMA-IR                                                       | $2.991 \pm 1.532$     | $3.671 \pm 0.955$       | $0.0154^{**}$ |
| * = t-test (student test) significant at level of $p < 0.05$  |                       |                         |               |
| ** = t-test (student test) significant at level of $p < 0.01$ |                       |                         |               |

Values are Presented as Mean  $\pm$  SD, hs-CRP = high sensitive C-Reactive Protein, FSG=fasting serum glucose, HOMA-IR = Homeostatic Model Assessment-Insulin Resistance. A significantly positive correlation between fasting insulin and L-carnitine was found in the two groups, Table 2.

**Table 2:** Correlation between Serum L-carnitine and Insulin in The Study Groups

|   | DM    | Control |
|---|-------|---------|
| R | 0.990 | 0.490   |
| p | 0.000 | 0.02    |
| N | 45    | 39      |

r = Pearson Correlation, p = Significance (2-tailed), N= number of subjects in the group.

## Discussion

The significantly ( $p < 0.05$ ) higher FSG, hs-CRP and HOMA-IR levels in diabetics with concurrent significantly ( $p < 0.05$ ) lowered L-carnitin and insulin levels compared to the controls (Table-2) may be explained by that the hyperglycemia during type 2 diabetes participates in the inflammation process which agree with Wu *et al.* [13], this inflammation could give a rise to insulin resistance, the same was found in Asimakidou *et al.* [14].

The significantly ( $p < 0.05$ ) lowered level of insulin secretion in diabetics could result from prolonged time exposure to the disease (table-2) which promote hypo-insulinemia and hyperglycemia as  $\beta$ -cells will be exhausted with time, agreeing with Faraj *et al.* [15] besides aging of diabetics as compared to controls (table -2) aging can cause gradual loss of  $\beta$ -cell mass, which agree with Nasteska *et al.* [16].

The significantly ( $p < 0.05$ ) lowered level of L-carnitine may comes from the hyperglycemia which lowers the level of L-carnitine, the same finding in Morgane *et al.* [17].

The significant ( $p < 0.05$ ) positive correlation between L-carnitine and insulin levels could be due to the effect of L-carnitine in ameliorating pancreatic oxidant, which is found by Mesallam *et al.* research [18] as L-carnitine act as antioxidant beside it's action as anti-inflammatory, agreeing with Cao *et al.* [19], promoting pancreatic secretion of insulin.

## Conclusion

The significantly ( $p < 0.05$ ) higher levels of serum L-carnitine and insulin with concurrent significantly ( $p < 0.05$ ) lower levels of FSG, hs-CRP and HOMA-IR in controls as compared to diabetics may illustrate the influence of L-carnitine in improving glucose level, and ameliorate insulin resistance, beside their anti-inflammatory effect, thereby

ameliorating diabetes and insulin resistance risks, demonstrating the importance of L-carnitine in the treatment of these two cases, however these findings need further investigations.

### Acknowledgment

The author would like to thank all employees in the National Center of Diabetes Treatment & Research; doctors, clinical chemistry laboratory staff and all the diabetic patients for their ongoing assistance throughout data collection and all peoples who help to achieve this work.

### Conflicts of Interest

Authors have no conflict of interest to declare.

### Funding

The authors did not receive support from any organization for this submitted work.

### References

1. Migdalis IN. Chronic Complications of Diabetes, Prevalence, Prevention, and Management. *Journal of Clinical Medicine*. 2024;13(23):7001.
2. Seiglie JA, Marcus ME, Ebert C, Prodromidis N, Geldsetzer P, Theilmann M, *et al*. Diabetes prevalence and its relationship with education, wealth, and BMI in 29 low-and middle-income countries. *Diabetes Care*. 2020;43(4):767-775.
3. Matalqah SM, Al-Tawalbeh DM. Medicinal plants potential against diabetes mellitus. *Diabetes*. 2025;9(10):11.
4. Wang Y, Yang S, Guan Q, Chen J, Zhang X, Zhang Y, *et al*. Effects of genetic variants of nuclear receptor  $\gamma$  on the risk of type 2 diabetes mellitus. *Journal of Diabetes Research*. 2019;Article ID 4902301.
5. Raheem MF, Ali SH, Shareef LG. Impact of serum levels of vitamin D on lipid profiles, glycemic indices, and insulin resistance in obese type 2 diabetes patients: An observational study. *F1000Research*. 2022;11:1002.
6. Namazi N, Moghaddam SS, Esmaeili S, Peimani M, Tehrani YS, Bandarian F, *et al*. Burden of type 2 diabetes mellitus and its risk factors in North Africa and the Middle East, 1990–2019: Findings from the Global Burden of Disease study 2019. *BMC Public Health*. 2024;24(1):98.
7. Sharma B, Schmidt L, Nguyen C, Kiernan S, Dexter-Meldrum J, Kuschner Z, *et al*. The effect of L-carnitine on critical illnesses such as traumatic brain injury (TBI), acute kidney injury (AKI), and hyperammonemia (HA). *Metabolites*. 2024;14(7):363.
8. Robert A, Moury J, Nendumba G, Hauqiart B, Vornicu O, Blackman S, *et al*. Carnitine deficiency in intensive care unit patients undergoing continuous renal replacement therapy—An underrecognized issue with potential for severe complications. *Journal of Intensive Medicine*. 2025;Jan 4.
9. Shimizu S, Takashima H, Tei R, Furukawa T, Okamura M, Kitai M, *et al*. Prevalence of carnitine deficiency and decreased carnitine levels in patients on peritoneal dialysis. *Nutrients*. 2019;11(11):2645.
10. Gheysari R, Nikbaf-Shandiz M, Hosseini AM, Rasaei N, Hosseini S, Bahari H, *et al*. The effects of L-carnitine supplementation on cardiovascular risk factors in participants with impaired glucose tolerance and diabetes: A systematic review and dose–response meta-analysis. *Diabetology & Metabolic Syndrome*. 2024;16(1):185.
11. Chen TW, Wang CH, Kuo FC, Lee MS, Lee GB. A dual-aptamer sandwich assay by detection of C-reactive protein in synovial fluid on an integrated microfluidic system for diagnosis of periprosthetic joint infection. *Sensors and Actuators B: Chemical*. 2025;1(424):136932.
12. Romero-Ferreiro V, García-Fernández L, Biscaia JM, Ferreiro CR, González-Soltero R, De la Fuente M, *et al*. Effect of probiotics on C-reactive protein levels in schizophrenia: Evidence from a systematic review and meta-analysis. *Complementary Therapies in Medicine*. 2025;9:10312.
13. Wu M, Hao Y, Wu X, Zhu M, Chen X, Qi J, *et al*. SirT7-mediated transcription of fascin in hyperglycemic glomerular endothelial cells contributes to EndMT in diabetic nephropathy: SirT7-mediated transcription of fascin contributes to EndMT. *Acta Biochimica et Biophysica Sinica*. 2024;56(4):586.
14. Asimakidou E, Saipuljumri EN, Lo CH, Zeng J. Role of metabolic dysfunction and inflammation along the liver–brain axis in animal models with obesity-induced neurodegeneration. *Neural Regeneration Research*. 2025;20(4):1069-76.
15. Faraj M. LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: A focus on white adipose tissue. *Journal of Biomedical Research*. 2020;34(4):251-259.
16. Nasteska D, Fine NH, Ashford FB, Cuozzo F, Vilorio K, Smith G, *et al*. PDX1 LOW MAFA LOW  $\beta$ -cells contribute to islet function and insulin release. *Nature Communications*. 2021;12(1):1-19.
17. Morgane DS, Abougabal KM, AbdelAziz MM, El-Gayed AS, Othman AO. Assessment of serum L-carnitine level in children with type 1 diabetes. *Alexandria Journal of Pediatrics*. 2021;34(1):23.
18. Mesallam DI, Alaa El-Din EA, Ibrahim MS, El-Fatah A, Salah S, Megahed EE. Molecular mechanisms of clozapine-induced pancreatic damage and its modulation by L-carnitine in a rat model. *Egyptian Society of Clinical Toxicology Journal*. 2024;12(1):182-99.
19. Cao X, Yuan R, Guo Y, Jia M, Wei Y, Zhou J, *et al*. L-carnitine improves muscle nutrient metabolism and intestinal health in high-fat-fed carp (*Cyprinus carpio*). *Aquaculture Nutrition*. 2025;1:5623889.